Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.

Cancer journal (Sudbury, Mass.) - 1 Jan 2000

Kudchadkar Ragini, Paraiso Kim H T, Smalley Keiran S M

Abstract excerpt

The discovery of activating BRAF mutations in ∼50% of all melanomas has proved to be a turning point in the therapeutic management of the disseminated disease. In this commentary, we review the latest research delineating the role of mutant BRAF in melanoma initiation and progression and discuss the remarkable 10-year journey leading up to the recent U.S. Food and Drug Administration approval of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Disease Progression

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Drug Resistance, Neoplasm

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 22453012
DOI: 10.1097/PPO.0b013e31824b436e
PMCID: PMC3314865

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.PMID 22453012Read ↗

Targeting BRAF in melanoma: biological and clinical challenges.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

BRAF in melanoma: current strategies and future directions.Semantic proximity Read ↗

Emerging insights into resistance to BRAF inhibitors in melanoma.Semantic proximity Read ↗

BRAF targeted therapy changes the treatment paradigm in melanoma.Semantic proximity Read ↗

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceSemantic proximity Read ↗

Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.Semantic proximity Read ↗

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.Semantic proximity Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

Biology and Treatment of BRAF Mutant Metastatic MelanomaSemantic proximity Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.